- Dosages
- Side effects in children
- Warnings & precautions in children
- Contra-indications in children
-
Interactions - PK
- Renal impairment
- References
Pharmacokinetics in children
Younger children (4 years) have a higher clearance than children of 12 and adults. Simulations show that younger children have lower serum levels than older children and adults [SmPC].
Average steady state trough concentrations in children ranged from 1.6 to 2.1 mcg/ml after 12, 24 and 48 hours. This is comparable to adults [SmPC].
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
dose recommendation of formulary compared to licensed use (on-label versus off-label)
No information is present at this moment.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Available formulations
No information is present at this moment.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Dosages
| Juvenile idiopathic arthritis (JIA), plaque psoriasis, psoriatic arthritis, enthesitis-related arthritis, hereditary autoinflammatory conditions including hyperimmunoglobulin D syndrome (HIDS), TNF receptor-associated periodic syndrome (TRAPS) |
|---|
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Renal impaiment in children > 3 months
GFR ≥10 ml/min/1.73m2: Dose adjustment not required.
GFR <10 ml/min/1.73m2: A general recommendation on dose adjustment cannot be provided.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here
Side effects in children
In general, side effects in children were similar in frequency and type to those seen in adults.
Headaches, nausea, vomiting and abdominal pain occur more often in children than in adults.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here
Contra-indications
No information available on specific contra indications in children.
The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here
Warnings & precautions in children
It is recommended that paediatric patients should be given all immunizations if possible
as per the applicable immunization guidelines before starting etanercept. There have been reports of IBD and uveitis in JIA patients during etanercept treatment.
The risk of malignancies developing in children and adolescents who have been treated with TNF antagonists cannot be excluded.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Interactions
The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
| Other immunosuppressants | ||
|---|---|---|
| L04AX01 | ||
| L04AX03 | ||
| Tumor necrosis factor alpha (TNF-alpha) inhibitors | ||
|---|---|---|
| L04AB04 | ||
| L04AB02 | ||
| Calcineurin inhibitors | ||
|---|---|---|
| L04AD01 | ||
| L04AD02 | ||
| Mammalian target of rapamycin (mTOR) kinase inhibitors | ||
|---|---|---|
| L04AH02 | ||
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
References
- Wyeth Europa Ltd., SmPC Enbrel EU/1/99/126/001 3-2-2010, www.emea.europa.eu
- Yim DS, et al, Population pharmacokinetic analysis and simulation of the time-concentration profile of etanercept in pediatric patients with juvenile rheumatoid arthritis., J Clin Pharmacol, 2005, Mar;45(3), 246-56
- Prince FH, et al, Initiating etanercept in a once weekly dose in children with juvenile idiopathic arthritis., Rheumatol Int, 2008, Feb;28(4), 397-8
- Prince FH, et al, Effectiveness of a once weekly double dose of etanercept in patients with juvenile idiopathic arthritis: a clinical study., Ann Rheum Dis, 2007, May;66(5), 704-5
- Horneff G, et al, Safety and efficacy of once weekly etanercept 0.8 mg/kg in a multicentre 12 week trial in active polyarticular course juvenile idiopathic arthritis., Rheumatology (Oxford)., 2009, Aug;48(8), 916-9
- Kuemmerle-Deschner JB, et al, Safety and efficacy of once-weekly application of Etanercept in children with juvenile idiopathic arthritis., Rheumatol Int, 2007, Dec;28(2), 153-6
- Immunex Corporation, Thousand Oaks, CA,, Product Information: ENBREL(R) subcutaneous injection, etanercept subcutaneous injection., 2008a.
- Aróstegui JI et al. , Etanercept plus colchicine treatment in a child with tumour necrosis factor receptor-associated periodic syndrome abolishes auto-inflammatory episodes without normalising the subclinical acute phase response. , Eur J Pediatr. , 2005 , Jan;164(1):, 13-6
- Bulua AC et al. , Efficacy of etanercept in the tumor necrosis factor receptor-associated periodic syndrome: a prospective, open-label, dose-escalation study., Arthritis Rheum. , 2012 , Mar;64(3):, 908-13
- Cantarini L et al. , Tumour necrosis factor receptor-associated periodic syndrome caused by a rare mutation in the TNFRSF1A gene, and with excellent response to etanercept treatment., Clin Exp Rheumatol., 2009 , Sep-Oct;27(5):, 890-1
- Dhanrajani A et al. , Modified regimen of etanercept for tumor necrosis factor receptor associated periodic syndrome (TRAPS) like illness., Indian Pediatr., 2014 , Jan;51(1):, 55-7
- Harambat J et al. , First report of rapidly progressive glomerulonephritis in tumor necrosis factor receptor-associated periodic syndrome., Arthritis Rheum. , 2008 , Oct;58(10), 3275-6
- Kostjukovits S et al. , Treatment of hyperimmunoglobulinemia D syndrome with biologics in children: review of the literature and Finnish experience., Eur J Pediatr. , 2015 , Feb 27
- Morbach H et al. , Tumor necrosis factor receptor 1-associated periodic syndrome without fever: cytokine profile before and during etanercept treatment., Rheumatol Int. , 2009 , Dec;30(2):, 207-12
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Changes
Changes
